JCEM：青少年皮质醇增敏治疗可预防成年雄激素过多的表型

EE-CA和PioFluMet化疗中会和化疗后CRP、CIMT、肉糖类和MSI变化

口服雌酪氨酸是较少年性激素但会的标准化疗，即使当这些小孩未不够年期的危险性。为了非常心血管疾病与血浆增敏化疗插手非高血压年轻人，在化疗中会和化疗后对性激素但会的制约，来自巴萨罗那该大学Sant Joan de Deu医院内黏液科的Lourdes Ibanez教授及其团队进行了一项研究者，该研究者推断出年轻人血浆增敏化疗插手不太可能防范成体部分性激素但会表改进型。该研究者结果的网站发表在2012年4同月1日的美国《临床内黏液新陈代谢杂志》（The journal of clinical endocrinology Co metabolism）上。该研究者是一项随机非盲次测试，病人是极高血浆血性疾病和性激素但会的非高血压较少年，且未不够年期的危险性（34由此可知；平均年龄16岁；身极高指数：23kg/m2）。研究者非常炔雌醇醋酸环丙孕酮（EE-CA）与小剂量吡咯列酮（7.5mg/d）、硫他米特（62.5mg/d）和二甲双萘（850mg/d）联合（PioFluMet）化疗18个同月的。化疗后随访6同月。观测性激素但会（蚯蚓性疾病、痤疮分数和血浆睾酮），诱因后血浆，循环系统C加成酶，胸动脉内膜中会层厚度，肌肉组成（吸收观测仪器），躯干糖类南区（磁共振成像）和孕酮。该研究者结果表明，EE-CA和PioFluMet同样缓解性激素但会，但有不同，以致制约其他结果。化疗后6个同月，PioFluMet化疗的小孩比EE-CA化疗的小孩有不够较高的诱因后血浆，不够较高的C加成酶素质和不够薄的内膜中会层，并且他们的肉糖类较较少，具有不够极高的髯身极高，以及不够不太可能有规律的孕酮。该研究者推断出，在非高血压的性激素但会的年轻人，PioFluMet化疗中会和化疗后的比心血管疾病的好。插手依靠年轻人性激素但会的减缓制约化疗后的表改进型。在年轻人，PioFluMet类似的插手不太可能防范成体部分性激素但会的表改进型，包含高血压和后生较高下。与冠心病无关的拓展阅读：

Diabetes Care：冠心病与心衰患者心脏交感神经活性减缓无关Diabetes Care：lixisenatide必需增加二甲双萘依靠不佳的2改进型冠心病人群的高血压2013 NIH 不够年期期冠心病(GDM)诊断声明JAMA：褪黑激素黏液减较少增加II改进型冠心病危险性DIABETES CARE：空腹高血压筛查不够年期冠心病添新证Eur J Endocrinol: 1改进型冠心病患者HbA1c素质过极高能直接加剧抑郁不够多信息再三点击：有关冠心病不够多资讯

Oral Contraception vs Insulin Sensitization for 18 Months in Nonobese Adolescents With Androgen Excess: Posttreatment Differences in C-Reactive Protein, Intima-Media Thickness, Visceral Adiposity, Insulin Sensitivity, and Menstrual Regularity BackgroundAn oral estro-progestagen is the standard medication given to adolescent girls with androgen excess, even when those girls are not at risk of pregnancy. AimThe aim of this study was to compare on-treatment and post-treatment effects of intervention with an oral contraceptive vs an insulin-sensitizing treatment for androgen excess in nonobese adolescents. DesignThis was a randomized, open-label trial. Study PopulationSubjects were nonobese adolescent girls with hyperinsulinemic androgen excess and without risk of pregnancy (mean age, 16 years; body mass index, 23 kg/m2; n = 34). InterventionsThe effects of treatment with ethinylestradiol-cyproteroneacetate (EE-CA) vs a low-dose combination of pioglitazone (7.5 mg/d), flutamide (62.5 mg/d), and metformin (850 mg/d) (PioFluMet) for 18 months were studied. Posttreatment follow-up was for 6 months. Main Outcome MeasuresAndrogen excess (hirsutism and acne scores and serum testosterone), glucose-stimulated insulinemia, circulating C-reactive protein, carotid intima media thickness, body composition (absorptiometry), abdominal fat partitioning (magnetic resonance imaging), and menstrual regularity were measured. ResultsEE-CA and PioFluMet attenuated androgen excess similarly but had divergent, and even opposing, effects on other outcomes. Six months posttreatment, the PioFluMet-treated girls had a lower glucose-induced insulinemia, a lower C-reactive protein level, and a thinner intima media than the EE-CA–treated girls, and they were viscerally less adipose, had a higher lean mass, and were more likely to he regular cycles. ConclusionsThe on-treatment and post-treatment effects of PioFluMet compared forably with those of oral contraception in nonobese adolescents with androgen excess. The intervention whereby androgen excess is reduced in adolescence influences the post-treatment phenotype. PioFluMet-like interventions in adolescence may thus hold the potential to prevent part of the androgen-excess phenotype in hood, including adiposity and subfertility.